Goat Anti-Human EML1 (K-16) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
BCASMC (B350-05) from European Collection of Cell Cultures (ECACC)
BAOSMC (B354-05) from European Collection of Cell Cultures (ECACC)
Adaptor for ABI 3700 (AB-0800) from ABgene
Biology Products:(Date:12/2/2009)...swire/ -- S*BIO Pte Ltd today announced data prese... at The American Society of Hematology 51st Annual... will be presented on the clinical results from th...g its safety, tolerability and pharmacokinetic/pha...g from 100 to 600 mg. These doses were administere...
(Date:12/2/2009).../PRNewswire-Asia/ -- Simcere Pharmaceutical Group,...ding pharmaceutical company,specializing in the de...,generic and proprietary pharmaceuticals in China,...ncluded in China,s National Drug Reimbursement Lis...f Human Resources and Social,Security on November ...
(Date:12/2/2009)...swire-Asia/ -- The world is going through,extraord...y is part of many,businesses and industries. It tu...ly immune to the economic downturn, because illnes...idst of the difficult times this year, the pharmac... R&D center in Shanghai, the largest of,its ki...
(Date:12/2/2009)...wire/ -- According to the National Institute of He...sed with diabetes already have some stage of diabe...the retina caused by leaky blood vessels, is a maj...is one of the most feared diabetic complications. ...had diabetes for 10 years or more will experience ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4